Kezar stock falls 11% after board rejects Concentra offer (update)
Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...
FierceBiotech5d
Kezar rejects Concentra bid that 'substantially undervalues' the biotech
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...
Kezar Life Rejects Proposal From Concentra; Board Adopts Limited Duration Stockholder Rights Plan
Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...
FierceBiotech13d
With Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisition
With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its ...
Nasdaq5d
Kezar Life Rejects Proposal From Concentra; Board Adopts Limited Duration Stockholder Rights Plan
(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...
Business Wire5d
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
After careful consideration and with the assistance of its independent financial and legal advisors, the Board unanimously concluded that the Concentra proposal substantially undervalues the Company.
Concentra Group Holdings Parent, Inc. (NYSE:CON) Receives $28.88 Average PT from Analysts
Shares of Concentra Group Holdings Parent, Inc. (NYSE:CON – Get Free Report) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, Ratings reports. One ...